Darby SC, Ewertz M, McGale P et al.. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013;368:987–998.

• PubMed
DarbySCEwertzMMcGaleP. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013;368:987–998. )| false
• Search Google Scholar
• Export Citation

Ky B, Vejpongsa P, Yeh ET et al.. Emerging paradigms in cardiomyopathies associated with cancer therapies. Circ Res 2013;113:754–764.

• PubMed
KyBVejpongsaPYehET. Emerging paradigms in cardiomyopathies associated with cancer therapies. Circ Res 2013;113:754–764. )| false
• Search Google Scholar
• Export Citation

Li W, Croce K, Steensma DP et al.. Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors. J Am Coll Cardiol 2015;66:1160–1178.

• PubMed
LiWCroceKSteensmaDP. Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors. J Am Coll Cardiol 2015;66:1160–1178. )| false
• Search Google Scholar
• Export Citation

Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med 2016;375:1457–1467.

• PubMed
MoslehiJJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med 2016;375:1457–1467. )| false
• Search Google Scholar
• Export Citation

O'Farrell S, Garmo H, Holmberg L et al.. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 2015;33:1243–1251.

• PubMed
O'FarrellSGarmoHHolmbergL. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 2015;33:1243–1251. )| false
• Search Google Scholar
• Export Citation

Schmid M, Sammon JD, Reznor G et al.. Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events. BJU Int 2015;118:221–229.

• PubMed
SchmidMSammonJDReznorG. Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events. BJU Int 2015;118:221–229. )| false
• Search Google Scholar
• Export Citation

Dess RT, Sun Y, Matuszak MM et al.. Cardiac events after radiation therapy: combined analysis of prospective multicenter trials for locally advanced non-small-cell lung cancer. J Clin Oncol 2017;35:1395–1402.

• PubMed
DessRTSunYMatuszakMM. Cardiac events after radiation therapy: combined analysis of prospective multicenter trials for locally advanced non-small-cell lung cancer. J Clin Oncol 2017;35:1395–1402. )| false
• Search Google Scholar
• Export Citation

Armenian SH, Xu L, Ky B et al.. Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study. J Clin Oncol 2016;34:1122–1130.

• PubMed
ArmenianSHXuLKyB. Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study. J Clin Oncol 2016;34:1122–1130. )| false
• Search Google Scholar
• Export Citation

Moslehi J. The cardiovascular perils of cancer survivorship. N Engl J Med 2013;368:1055–1056.

• PubMed
MoslehiJ. The cardiovascular perils of cancer survivorship. N Engl J Med 2013;368:1055–1056. )| false
• Search Google Scholar
• Export Citation

Moslehi J, Cheng S. Cardio-oncology: it takes two to translate. Sci Transl Med 2013;5:187fs120.

• PubMed
MoslehiJChengS. Cardio-oncology: it takes two to translate. Sci Transl Med 2013;5:187fs120. )| false
• Search Google Scholar
• Export Citation

Lipshultz SE, Colan SD, Gelber RD et al.. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991;324:808–815.

• PubMed
LipshultzSEColanSDGelberRD. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991;324:808–815. )| false
• Search Google Scholar
• Export Citation

Lipshultz SE, Lipsitz SR, Mone SM et al.. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995;332:1738–1743.

• PubMed
LipshultzSELipsitzSRMoneSM. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995;332:1738–1743. )| false
• Search Google Scholar
• Export Citation

Smith LA, Cornelius VR, Plummer CJ et al.. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 2010;10:337.

• PubMed
SmithLACorneliusVRPlummerCJ. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 2010;10:337. )| false
• Search Google Scholar
• Export Citation

Minotti G, Menna P, Salvatorelli E et al.. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185–229.

• PubMed
MinottiGMennaPSalvatorelliE. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185–229. )| false
• Search Google Scholar
• Export Citation

Zhang S, Liu X, Bawa-Khalfe T et al.. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 2012;18:1639–1642.

• PubMed
ZhangSLiuXBawa-KhalfeT. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 2012;18:1639–1642. )| false
• Search Google Scholar
• Export Citation

Koelwyn GJ, Khouri M, Mackey JR et al.. Running on empty: cardiovascular reserve capacity and late effects of therapy in cancer survivorship. J Clin Oncol 2012;30:4458–4461.

• PubMed
KoelwynGJKhouriMMackeyJR. Running on empty: cardiovascular reserve capacity and late effects of therapy in cancer survivorship. J Clin Oncol 2012;30:4458–4461. )| false
• Search Google Scholar
• Export Citation

Lotrionte M, Biondi-Zoccai G, Abbate A et al.. Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am J Cardiol 2013;112:1980–1984.

• PubMed
LotrionteMBiondi-ZoccaiGAbbateA. Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am J Cardiol 2013;112:1980–1984. )| false
• Search Google Scholar
• Export Citation

Romond EH, Jeong JH, Rastogi P et al.. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012;30:3792–3799.

• PubMed
RomondEHJeongJHRastogiP. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012;30:3792–3799. )| false
• Search Google Scholar
• Export Citation

Russell SD, Blackwell KL, Lawrence J et al.. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol 2010;28:3416–3421.

• PubMed
RussellSDBlackwellKLLawrenceJ. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol 2010;28:3416–3421. )| false
• Search Google Scholar
• Export Citation

Cardinale D, Colombo A, Bacchiani G et al.. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015;131:1981–1988.

• PubMed
CardinaleDColomboABacchianiG. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015;131:1981–1988. )| false
• Search Google Scholar
• Export Citation

Drafts BC, Twomley KM, D'Agostino R Jr. et al.. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging 2013;6:877–885.

• PubMed
DraftsBCTwomleyKMD'AgostinoRJr.. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging 2013;6:877–885. )| false
• Search Google Scholar
• Export Citation

Groarke J, Tong D, Khambhati J et al.. Breast cancer therapies and cardiomyopathy. Med Clin North Am 2012;96:1001–1019.

• PubMed
GroarkeJTongDKhambhatiJ. Breast cancer therapies and cardiomyopathy. Med Clin North Am 2012;96:1001–1019. )| false
• Search Google Scholar
• Export Citation

Johnson DB, Balko JM, Compton ML et al.. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016;375:1749–1755.

• PubMed
JohnsonDBBalkoJMComptonML. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016;375:1749–1755. )| false
• Search Google Scholar
• Export Citation

Moslehi JJ, Salem JE, Sosman JA et al.. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 2018;391:933.

• PubMed
MoslehiJJSalemJESosmanJA. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 2018;391:933. )| false
• Search Google Scholar
• Export Citation

Daniels LA, Krol AD, de Graaf MA et al.. Screening for coronary artery disease after mediastinal irradiation in Hodgkin lymphoma survivors: phase II study of indication and acceptancedagger. Ann Oncol 2014;25:1198–1203.

• PubMed
DanielsLAKrolADde GraafMA. Screening for coronary artery disease after mediastinal irradiation in Hodgkin lymphoma survivors: phase II study of indication and acceptancedagger. Ann Oncol 2014;25:1198–1203. )| false
• Search Google Scholar
• Export Citation

Cardinale D, Colombo A, Lamantia G et al.. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010;55:213–220.

• PubMed
CardinaleDColomboALamantiaG. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010;55:213–220. )| false
• Search Google Scholar
• Export Citation

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992;327:685–691.

• PubMed
Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992;327:685–691. )| false
• Search Google Scholar
• Export Citation

Thakur A, Witteles RM. Cancer therapy-induced left ventricular dysfunction: interventions and prognosis. J Card Fail 2014;20:155–158.

• PubMed
ThakurAWittelesRM. Cancer therapy-induced left ventricular dysfunction: interventions and prognosis. J Card Fail 2014;20:155–158. )| false
• Search Google Scholar
• Export Citation

Silber JH, Cnaan A, Clark BJ et al.. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 2004;22:820–828.

• PubMed
SilberJHCnaanAClarkBJ. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 2004;22:820–828. )| false
• Search Google Scholar
• Export Citation

Adamo V, Ricciardi GR, Adamo B et al.. The risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer population. Oncology 2014;86:16–21.

• PubMed
AdamoVRicciardiGRAdamoB. The risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer population. Oncology 2014;86:16–21. )| false
• Search Google Scholar
• Export Citation

Mitra MS, Donthamsetty S, White B, Mehendale HM. High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity. Toxicol Appl Pharmacol 2008;231:413–422.

• PubMed
MitraMSDonthamsettySWhiteBMehendaleHM. High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity. Toxicol Appl Pharmacol 2008;231:413–422. )| false
• Search Google Scholar
• Export Citation

Scott E, Daley AJ, Doll H et al.. Effects of an exercise and hypocaloric healthy eating program on biomarkers associated with long-term prognosis after early-stage breast cancer: a randomized controlled trial. Cancer Causes Control 2013;24:181–191.

• PubMed
ScottEDaleyAJDollH. Effects of an exercise and hypocaloric healthy eating program on biomarkers associated with long-term prognosis after early-stage breast cancer: a randomized controlled trial. Cancer Causes Control 2013;24:181–191. )| false
• Search Google Scholar
• Export Citation

Ferrari N, Tosetti F, De Flora S et al.. Diet-derived phytochemicals: from cancer chemoprevention to cardio-oncological prevention. Curr Drug Targets 2011;12:1909–1924.

• PubMed
FerrariNTosettiFDe FloraS. Diet-derived phytochemicals: from cancer chemoprevention to cardio-oncological prevention. Curr Drug Targets 2011;12:1909–1924. )| false
• Search Google Scholar
• Export Citation

Dolinsky VW, Rogan KJ, Sung MM et al.. Both aerobic exercise and resveratrol supplementation attenuate doxorubicin-induced cardiac injury in mice. Am J Physiol Endocrinol Metab 2013;305:E243–253.

• PubMed
DolinskyVWRoganKJSungMM. Both aerobic exercise and resveratrol supplementation attenuate doxorubicin-induced cardiac injury in mice. Am J Physiol Endocrinol Metab 2013;305:E243–253. )| false
• Search Google Scholar
• Export Citation

Emter CA, Bowles DK. Curing the cure: utilizing exercise to limit cardiotoxicity. Med Sci Sports Exerc 2008;40:806–807.

• PubMed
EmterCABowlesDK. Curing the cure: utilizing exercise to limit cardiotoxicity. Med Sci Sports Exerc 2008;40:806–807. )| false
• Search Google Scholar
• Export Citation

Hydock DS, Lien CY, Jensen BT et al.. Exercise preconditioning provides long-term protection against early chronic doxorubicin cardiotoxicity. Integr Cancer Ther 2011;10:47–57.

• PubMed
HydockDSLienCYJensenBT. Exercise preconditioning provides long-term protection against early chronic doxorubicin cardiotoxicity. Integr Cancer Ther 2011;10:47–57. )| false
• Search Google Scholar
• Export Citation

Jones LW, Liu Q, Armstrong GT et al.. Exercise and risk of major cardiovascular events in adult survivors of childhood hodgkin lymphoma: a report from the childhood cancer survivor study. J Clin Oncol 2014;32:3643–3650.

• PubMed
JonesLWLiuQArmstrongGT. Exercise and risk of major cardiovascular events in adult survivors of childhood hodgkin lymphoma: a report from the childhood cancer survivor study. J Clin Oncol 2014;32:3643–3650. )| false
• Search Google Scholar
• Export Citation

Jones LW, Habel LA, Weltzien E et al.. Exercise and risk of cardiovascular events in women with nonmetastatic breast cancer. J Clin Oncol 2016;34:2743–2749.

• PubMed
JonesLWHabelLAWeltzienE. Exercise and risk of cardiovascular events in women with nonmetastatic breast cancer. J Clin Oncol 2016;34:2743–2749. )| false
• Search Google Scholar
• Export Citation

Rock E, DeMichele A. Nutritional approaches to late toxicities of adjuvant chemotherapy in breast cancer survivors. J Nutr 2003;133:3785S–3793S.

• PubMed
RockEDeMicheleA. Nutritional approaches to late toxicities of adjuvant chemotherapy in breast cancer survivors. J Nutr 2003;133:3785S–3793S. )| false
• Search Google Scholar
• Export Citation

Sturgeon KM, Ky B, Libonati JR, Schmitz KH. The effects of exercise on cardiovascular outcomes before, during, and after treatment for breast cancer. Breast Cancer Res Treat 2014;143:219–226.

• PubMed
SturgeonKMKyBLibonatiJRSchmitzKH. The effects of exercise on cardiovascular outcomes before, during, and after treatment for breast cancer. Breast Cancer Res Treat 2014;143:219–226. )| false
• Search Google Scholar
• Export Citation

Hunt SA, Baker DW, Chin MH et al.. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2001;38:2101–2113.

• PubMed
HuntSABakerDWChinMH. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2001;38:2101–2113. )| false
• Search Google Scholar
• Export Citation

Jones LW, Eves ND, Haykowsky M et al.. Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction. Lancet Oncol 2009;10:598–605.

• PubMed
JonesLWEvesNDHaykowskyM. Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction. Lancet Oncol 2009;10:598–605. )| false
• Search Google Scholar
• Export Citation

The Criteria Committee of the New York Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels (9th ed). Boston, MA: Little & Brown; 1994.

• PubMed
The Criteria Committee of the New York Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels (9th ed). Boston, MA: Little & Brown; 1994. )| false
• Search Google Scholar
• Export Citation

Carver JR, Shapiro CL, Ng A et al.. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol 2007;25:3991–4008.

• PubMed
CarverJRShapiroCLNgA. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol 2007;25:3991–4008. )| false
• Search Google Scholar
• Export Citation

Shankar SM, Marina N, Hudson MM et al.. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children's Oncology Group. Pediatrics 2008;121:e387–396.

• PubMed
ShankarSMMarinaNHudsonMM. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children's Oncology Group. Pediatrics 2008;121:e387–396. )| false
• Search Google Scholar
• Export Citation

Earle CC. Cancer survivorship research and guidelines: maybe the cart should be beside the horse. J Clin Oncol 2007;25:3800–3801.

• PubMed
EarleCC. Cancer survivorship research and guidelines: maybe the cart should be beside the horse. J Clin Oncol 2007;25:3800–3801. )| false
• Search Google Scholar
• Export Citation

Armenian SH, Hudson MM, Mulder RL et al.. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 2015;16:e123–136.

• PubMed
ArmenianSHHudsonMMMulderRL. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 2015;16:e123–136. )| false
• Search Google Scholar
• Export Citation

Yeh JM, Nohria A, Diller L. Routine echocardiography screening for asymptomatic left ventricular dysfunction in childhood cancer survivors: a model-based estimation of the clinical and economic effects. Ann Intern Med 2014;160:661–671.

• PubMed
YehJMNohriaADillerL. Routine echocardiography screening for asymptomatic left ventricular dysfunction in childhood cancer survivors: a model-based estimation of the clinical and economic effects. Ann Intern Med 2014;160:661–671. )| false
• Search Google Scholar
• Export Citation

Steingart RM, Liu JE, Oeffinger KC. Cost-effectiveness of screening for asymptomatic left ventricular dysfunction in childhood cancer survivors. Ann Intern Med 2014;160:731–732.

• PubMed
SteingartRMLiuJEOeffingerKC. Cost-effectiveness of screening for asymptomatic left ventricular dysfunction in childhood cancer survivors. Ann Intern Med 2014;160:731–732. )| false
• Search Google Scholar
• Export Citation

Plana JC, Galderisi M, Barac A et al.. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2014;27:911–939.

• PubMed
PlanaJCGalderisiMBaracA. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2014;27:911–939. )| false
• Search Google Scholar
• Export Citation

Armenian SH, Lacchetti C, Barac A et al.. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2017;35:893–911.

• PubMed
ArmenianSHLacchettiCBaracA. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2017;35:893–911. )| false
• Search Google Scholar
• Export Citation

Yancy CW, Jessup M, Bozkurt B et al.. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:e147–239.

• PubMed
YancyCWJessupMBozkurtB. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:e147–239. )| false
• Search Google Scholar
• Export Citation

Wang K, Eblan MJ, Deal AM et al.. Cardiac toxicity after radiotherapy for stage III non-small-cell lung cancer: pooled analysis of dose-escalation trials delivering 70 to 90 Gy. J Clin Oncol 2017;35:1387–1394.

• PubMed
WangKEblanMJDealAM. Cardiac toxicity after radiotherapy for stage III non-small-cell lung cancer: pooled analysis of dose-escalation trials delivering 70 to 90 Gy. J Clin Oncol 2017;35:1387–1394. )| false
• Search Google Scholar
• Export Citation

Bowles EJ, Wellman R, Feigelson HS et al.. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 2012;104:1293–1305.

• PubMed
BowlesEJWellmanRFeigelsonHS. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 2012;104:1293–1305. )| false
• Search Google Scholar
• Export Citation

Guenancia C, Lefebvre A, Cardinale D et al.. Obesity as a risk factor for anthracyclines and trastuzumab cardiotoxicity in breast cancer: a systematic review and meta-analysis. J Clin Oncol 2016;34:3157–3165.

• PubMed
GuenanciaCLefebvreACardinaleD. Obesity as a risk factor for anthracyclines and trastuzumab cardiotoxicity in breast cancer: a systematic review and meta-analysis. J Clin Oncol 2016;34:3157–3165. )| false
• Search Google Scholar
• Export Citation

Hershman DL, Till C, Shen S et al.. Association of cardiovascular risk factors with cardiac events and survival outcomes among patients with breast cancer enrolled in SWOG clinical trials. J Clin Oncol 2018:2710–2717.

• PubMed
HershmanDLTillCShenS. Association of cardiovascular risk factors with cardiac events and survival outcomes among patients with breast cancer enrolled in SWOG clinical trials. J Clin Oncol 2018:2710–2717. )| false
• Search Google Scholar
• Export Citation

Tan-Chiu E, Yothers G, Romond E et al.. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:7811–7819.

• PubMed
Tan-ChiuEYothersGRomondE. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:7811–7819. )| false
• Search Google Scholar
• Export Citation

Groarke JD, Nguyen PL, Nohria A et al.. Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease. Eur Heart J 2014;35:612–623.

• PubMed
GroarkeJDNguyenPLNohriaA. Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease. Eur Heart J 2014;35:612–623. )| false
• Search Google Scholar
• Export Citation

Thavendiranathan P, Poulin F, Lim KD et al.. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol 2014;63:2751–2768.

• PubMed
ThavendiranathanPPoulinFLimKD. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol 2014;63:2751–2768. )| false
• Search Google Scholar
• Export Citation

Monsuez JJ. Detection and prevention of cardiac complications of cancer chemotherapy. Arch Cardiovasc Dis 2012;105:593–604.

• PubMed
MonsuezJJ. Detection and prevention of cardiac complications of cancer chemotherapy. Arch Cardiovasc Dis 2012;105:593–604. )| false
• Search Google Scholar
• Export Citation

Sawaya H, Sebag IA, Plana JC et al.. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 2012;5:596–603.

• PubMed
SawayaHSebagIAPlanaJC. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 2012;5:596–603. )| false
• Search Google Scholar
• Export Citation

Thigpen SC, Geraci SA. Prediction of anthracycline-induced left ventricular dysfunction by cardiac troponins. South Med J 2012;105:659–664.

• PubMed
ThigpenSCGeraciSA. Prediction of anthracycline-induced left ventricular dysfunction by cardiac troponins. South Med J 2012;105:659–664. )| false
• Search Google Scholar
• Export Citation

Scott JM, Khakoo A, Mackey JR et al.. Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms. Circulation 2011;124:642–650.

• PubMed
ScottJMKhakooAMackeyJR. Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms. Circulation 2011;124:642–650. )| false
• Search Google Scholar
• Export Citation

Beckjord EB, Reynolds KA, van Londen GJ et al.. Population-level trends in posttreatment cancer survivors' concerns and associated receipt of care: results from the 2006 and 2010 LIVESTRONG surveys. J Psychosoc Oncol 2014;32:125–151.

• PubMed
BeckjordEBReynoldsKAvan LondenGJ. Population-level trends in posttreatment cancer survivors' concerns and associated receipt of care: results from the 2006 and 2010 LIVESTRONG surveys. J Psychosoc Oncol 2014;32:125–151. )| false
• Search Google Scholar
• Export Citation

Ribeiro Pereira ACP, Koifman RJ, Bergmann A. Incidence and risk factors of lymphedema after breast cancer treatment: 10 years of follow-up. Breast 2017;36:67–73.

• PubMed
Ribeiro PereiraACPKoifmanRJBergmannA. Incidence and risk factors of lymphedema after breast cancer treatment: 10 years of follow-up. Breast 2017;36:67–73. )| false
• Search Google Scholar
• Export Citation

Hayes SC, Janda M, Ward LC et al.. Lymphedema following gynecological cancer: results from a prospective, longitudinal cohort study on prevalence, incidence and risk factors. Gynecol Oncol 2017;146:623–629.

• PubMed
HayesSCJandaMWardLC. Lymphedema following gynecological cancer: results from a prospective, longitudinal cohort study on prevalence, incidence and risk factors. Gynecol Oncol 2017;146:623–629. )| false
• Search Google Scholar
• Export Citation

Gjorup CA, Groenvold M, Hendel HW et al.. Health-related quality of life in melanoma patients: Impact of melanoma-related limb lymphoedema. Eur J Cancer 2017;85:122–132.

• PubMed
GjorupCAGroenvoldMHendelHW. Health-related quality of life in melanoma patients: Impact of melanoma-related limb lymphoedema. Eur J Cancer 2017;85:122–132. )| false
• Search Google Scholar
• Export Citation

Vassard D, Olsen MH, Zinckernagel L et al.. Psychological consequences of lymphoedema associated with breast cancer: a prospective cohort study. Eur J Cancer 2010;46:3211–3218.

• PubMed
VassardDOlsenMHZinckernagelL. Psychological consequences of lymphoedema associated with breast cancer: a prospective cohort study. Eur J Cancer 2010;46:3211–3218. )| false
• Search Google Scholar
• Export Citation

Syrowatka A, Motulsky A, Kurteva S et al.. Predictors of distress in female breast cancer survivors: a systematic review. Breast Cancer Res Treat 2017;165:229–245.

• PubMed
SyrowatkaAMotulskyAKurtevaS. Predictors of distress in female breast cancer survivors: a systematic review. Breast Cancer Res Treat 2017;165:229–245. )| false
• Search Google Scholar
• Export Citation

Dominick SA, Natarajan L, Pierce JP et al.. The psychosocial impact of lymphedema-related distress among breast cancer survivors in the WHEL Study. Psychooncology 2014;23:1049–1056.

• PubMed
DominickSANatarajanLPierceJP. The psychosocial impact of lymphedema-related distress among breast cancer survivors in the WHEL Study. Psychooncology 2014;23:1049–1056. )| false
• Search Google Scholar
• Export Citation

Hormes JM, Bryan C, Lytle LA et al.. Impact of lymphedema and arm symptoms on quality of life in breast cancer survivors. Lymphology 2010;43:1–13.

• PubMed
HormesJMBryanCLytleLA. Impact of lymphedema and arm symptoms on quality of life in breast cancer survivors. Lymphology 2010;43:1–13. )| false
• Search Google Scholar
• Export Citation

McWayne J, Heiney SP. Psychologic and social sequelae of secondary lymphedema: a review. Cancer 2005;104:457–466.

• PubMed
McWayneJHeineySP. Psychologic and social sequelae of secondary lymphedema: a review. Cancer 2005;104:457–466. )| false
• Search Google Scholar
• Export Citation

Boyages J, Kalfa S, Xu Y et al.. Worse and worse off: the impact of lymphedema on work and career after breast cancer. Springerplus 2016;5:657.

• PubMed
BoyagesJKalfaSXuY. Worse and worse off: the impact of lymphedema on work and career after breast cancer. Springerplus 2016;5:657. )| false
• Search Google Scholar
• Export Citation

Asdourian MS, Swaroop MN, Sayegh HE et al.. Association between precautionary behaviors and breast cancer-related lymphedema in patients undergoing bilateral surgery. J Clin Oncol 2017;35:3934–3941.

• PubMed
AsdourianMSSwaroopMNSayeghHE. Association between precautionary behaviors and breast cancer-related lymphedema in patients undergoing bilateral surgery. J Clin Oncol 2017;35:3934–3941. )| false
• Search Google Scholar
• Export Citation

DiSipio T, Rye S, Newman B, Hayes S. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol 2013;14:500–515.

• PubMed
DiSipioTRyeSNewmanBHayesS. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol 2013;14:500–515. )| false
• Search Google Scholar
• Export Citation

Kilbreath SL, Refshauge KM, Beith JM et al.. Risk factors for lymphoedema in women with breast cancer: a large prospective cohort. Breast 2016;28:29–36.

• PubMed
KilbreathSLRefshaugeKMBeithJM. Risk factors for lymphoedema in women with breast cancer: a large prospective cohort. Breast 2016;28:29–36. )| false
• Search Google Scholar
• Export Citation

Kuroda K, Yamamoto Y, Yanagisawa M et al.. Risk factors and a prediction model for lower limb lymphedema following lymphadenectomy in gynecologic cancer: a hospital-based retrospective cohort study. BMC Womens Health 2017;17:50.

• PubMed
KurodaKYamamotoYYanagisawaM. Risk factors and a prediction model for lower limb lymphedema following lymphadenectomy in gynecologic cancer: a hospital-based retrospective cohort study. BMC Womens Health 2017;17:50. )| false
• Search Google Scholar
• Export Citation

Black DM, Jiang J, Kuerer HM et al.. Racial disparities in adoption of axillary sentinel lymph node biopsy and lymphedema risk in women with breast cancer. JAMA Surg 2014;149:788–796.

• PubMed
BlackDMJiangJKuererHM. Racial disparities in adoption of axillary sentinel lymph node biopsy and lymphedema risk in women with breast cancer. JAMA Surg 2014;149:788–796. )| false
• Search Google Scholar
• Export Citation

Li CZ, Zhang P, Li RW et al.. Axillary lymph node dissection versus sentinel lymph node biopsy alone for early breast cancer with sentinel node metastasis: a meta-analysis. Eur J Surg Oncol 2015;41:958–966.

• PubMed
LiCZZhangPLiRW. Axillary lymph node dissection versus sentinel lymph node biopsy alone for early breast cancer with sentinel node metastasis: a meta-analysis. Eur J Surg Oncol 2015;41:958–966. )| false
• Search Google Scholar
• Export Citation

Norman SA, Localio AR, Kallan MJ et al.. Risk factors for lymphedema after breast cancer treatment. Cancer Epidemiol Biomarkers Prev 2010;19:2734–2746.

• PubMed
NormanSALocalioARKallanMJ. Risk factors for lymphedema after breast cancer treatment. Cancer Epidemiol Biomarkers Prev 2010;19:2734–2746. )| false
• Search Google Scholar
• Export Citation

de Vries M, Hoekstra HJ, Hoekstra-Weebers JE. Quality of life after axillary or groin sentinel lymph node biopsy, with or without completion lymph node dissection, in patients with cutaneous melanoma. Ann Surg Oncol 2009;16:2840–2847.

• PubMed
de VriesMHoekstraHJHoekstra-WeebersJE. Quality of life after axillary or groin sentinel lymph node biopsy, with or without completion lymph node dissection, in patients with cutaneous melanoma. Ann Surg Oncol 2009;16:2840–2847. )| false
• Search Google Scholar
• Export Citation

Huang J, Yu N, Wang X, Long X. Incidence of lower limb lymphedema after vulvar cancer: a systematic review and meta-analysis. Medicine (Baltimore) 2017;96:e8722.

• PubMed
HuangJYuNWangXLongX. Incidence of lower limb lymphedema after vulvar cancer: a systematic review and meta-analysis. Medicine (Baltimore) 2017;96:e8722. )| false
• Search Google Scholar
• Export Citation

Ahmed RL, Schmitz KH, Prizment AE, Folsom AR. Risk factors for lymphedema in breast cancer survivors, the Iowa Women's Health Study. Breast Cancer Res Treat 2011;130:981–991.

• PubMed
AhmedRLSchmitzKHPrizmentAEFolsomAR. Risk factors for lymphedema in breast cancer survivors, the Iowa Women's Health Study. Breast Cancer Res Treat 2011;130:981–991. )| false
• Search Google Scholar
• Export Citation

Dominick SA, Madlensky L, Natarajan L, Pierce JP. Risk factors associated with breast cancer-related lymphedema in the WHEL Study. J Cancer Surviv 2013;7:115–123.

• PubMed
DominickSAMadlenskyLNatarajanLPierceJP. Risk factors associated with breast cancer-related lymphedema in the WHEL Study. J Cancer Surviv 2013;7:115–123. )| false
• Search Google Scholar
• Export Citation

Asdourian MS, Skolny MN, Brunelle C et al.. Precautions for breast cancer-related lymphoedema: risk from air travel, ipsilateral arm blood pressure measurements, skin puncture, extreme temperatures, and cellulitis. Lancet Oncol 2016;17:e392–405.

• PubMed
AsdourianMSSkolnyMNBrunelleC. Precautions for breast cancer-related lymphoedema: risk from air travel, ipsilateral arm blood pressure measurements, skin puncture, extreme temperatures, and cellulitis. Lancet Oncol 2016;17:e392–405. )| false
• Search Google Scholar
• Export Citation

Ferguson CM, Swaroop MN, Horick N et al.. Impact of ipsilateral blood draws, injections, blood pressure measurements, and air travel on the risk of lymphedema for patients treated for breast cancer. J Clin Oncol 2016;34:691–698.

• PubMed
FergusonCMSwaroopMNHorickN. Impact of ipsilateral blood draws, injections, blood pressure measurements, and air travel on the risk of lymphedema for patients treated for breast cancer. J Clin Oncol 2016;34:691–698. )| false
• Search Google Scholar
• Export Citation

Li L, Yuan L, Chen X et al.. Current treatments for breast cancer-related lymphoedema: a systematic review. Asian Pac J Cancer Prev 2016;17:4875–4883.

• PubMed
LiLYuanLChenX. Current treatments for breast cancer-related lymphoedema: a systematic review. Asian Pac J Cancer Prev 2016;17:4875–4883. )| false
• Search Google Scholar
• Export Citation

Paskett ED, Dean JA, Oliveri JM, Harrop JP. Cancer-related lymphedema risk factors, diagnosis, treatment, and impact: a review. J Clin Oncol 2012;30:3726–3733.

• PubMed
PaskettEDDeanJAOliveriJMHarropJP. Cancer-related lymphedema risk factors, diagnosis, treatment, and impact: a review. J Clin Oncol 2012;30:3726–3733. )| false
• Search Google Scholar
• Export Citation

Lymphology ISo. The diagnosis and treatment of peripheral lymphedema: 2013 Consensus Document of the International Society of Lymphology. Lymphology 2013;46:1–11.

• PubMed
Lymphology ISo. The diagnosis and treatment of peripheral lymphedema: 2013 Consensus Document of the International Society of Lymphology. Lymphology 2013;46:1–11. )| false
• Search Google Scholar
• Export Citation

Smile TD, Tendulkar R, Schwarz G et al.. A review of treatment for breast cancer-related lymphedema: Paradigms for clinical practice. Am J Clin Oncol 2018;41:178–190.

• PubMed
SmileTDTendulkarRSchwarzG. A review of treatment for breast cancer-related lymphedema: Paradigms for clinical practice. Am J Clin Oncol 2018;41:178–190. )| false
• Search Google Scholar
• Export Citation

Stout Gergich NL, Pfalzer LA, McGarvey C et al.. Preoperative assessment enables the early diagnosis and successful treatment of lymphedema. Cancer 2008;112:2809–2819.

• PubMed
Stout GergichNLPfalzerLAMcGarveyC. Preoperative assessment enables the early diagnosis and successful treatment of lymphedema. Cancer 2008;112:2809–2819. )| false
• Search Google Scholar
• Export Citation

Ezzo J, Manheimer E, McNeely ML et al.. Manual lymphatic drainage for lymphedema following breast cancer treatment. Cochrane Database Syst Rev 2015:CD003475.

• PubMed
EzzoJManheimerEMcNeelyML. Manual lymphatic drainage for lymphedema following breast cancer treatment. Cochrane Database Syst Rev 2015:CD003475. )| false
• Search Google Scholar
• Export Citation

Shao Y, Zhong DS. Manual lymphatic drainage for breast cancer-related lymphoedema. Eur J Cancer Care (Engl) 2017;26.

• PubMed
ShaoYZhongDS. Manual lymphatic drainage for breast cancer-related lymphoedema. Eur J Cancer Care (Engl) 2017;26. )| false
• Search Google Scholar
• Export Citation

Brown JC, John GM, Segal S et al.. Physical activity and lower limb lymphedema among uterine cancer survivors. Med Sci Sports Exerc 2013;45:2091–2097.

• PubMed
BrownJCJohnGMSegalS. Physical activity and lower limb lymphedema among uterine cancer survivors. Med Sci Sports Exerc 2013;45:2091–2097. )| false
• Search Google Scholar
• Export Citation

Courneya KS, Segal RJ, Mackey JR et al.. Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. J Clin Oncol 2007;25:4396–4404.

• PubMed
CourneyaKSSegalRJMackeyJR. Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. J Clin Oncol 2007;25:4396–4404. )| false
• Search Google Scholar
• Export Citation

Hayes SC, Speck RM, Reimet E et al.. Does the effect of weight lifting on lymphedema following breast cancer differ by diagnostic method: results from a randomized controlled trial. Breast Cancer Res Treat 2011;130:227–234.

• PubMed
HayesSCSpeckRMReimetE. Does the effect of weight lifting on lymphedema following breast cancer differ by diagnostic method: results from a randomized controlled trial. Breast Cancer Res Treat 2011;130:227–234. )| false
• Search Google Scholar
• Export Citation

Nelson NL. Breast cancer-related lymphedema and resistance exercise: a systematic review. J Strength Cond Res 2016;30:2656–2665.

• PubMed
NelsonNL. Breast cancer-related lymphedema and resistance exercise: a systematic review. J Strength Cond Res 2016;30:2656–2665. )| false
• Search Google Scholar
• Export Citation

Schmitz KH, Ahmed RL, Troxel A et al.. Weight lifting in women with breast-cancer-related lymphedema. N Engl J Med 2009;361:664–673.

• PubMed
SchmitzKHAhmedRLTroxelA. Weight lifting in women with breast-cancer-related lymphedema. N Engl J Med 2009;361:664–673. )| false
• Search Google Scholar
• Export Citation

Schmitz KH, Ahmed RL, Troxel AB et al.. Weight lifting for women at risk for breast cancer-related lymphedema: a randomized trial. JAMA 2010;304:2699–2705.

• PubMed
SchmitzKHAhmedRLTroxelAB. Weight lifting for women at risk for breast cancer-related lymphedema: a randomized trial. JAMA 2010;304:2699–2705. )| false
• Search Google Scholar
• Export Citation

Schmitz KH, Courneya KS, Matthews C et al.. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 2010;42:1409–1426.

• PubMed
SchmitzKHCourneyaKSMatthewsC. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 2010;42:1409–1426. )| false
• Search Google Scholar
• Export Citation

Position Statement of the National Lymphedema Network: Exercise. NLN Medical Advisory Committee; 2011. Available at: https://nationallymphedemanetwork.org/assets/docs/position_papers/Exercise.pdf. Accessed June 26, 2018.

• PubMed
Position Statement of the National Lymphedema Network: Exercise. NLN Medical Advisory Committee; 2011. Available at: https://nationallymphedemanetwork.org/assets/docs/position_papers/Exercise.pdf. Accessed June 26, 2018. )| false
• Search Google Scholar
• Export Citation

Irwin M, ed ACSM's Guide to Exercise and Cancer Survivorship. Champaign, IL: The American College of Sports Medicine; 2012.

• PubMed
IrwinM, ed ACSM's Guide to Exercise and Cancer Survivorship. Champaign, IL: The American College of Sports Medicine; 2012. )| false
• Search Google Scholar
• Export Citation

Brown JC, Troxel AB, Schmitz KH. Safety of weightlifting among women with or at risk for breast cancer-related lymphedema: musculoskeletal injuries and health care use in a weightlifting rehabilitation trial. Oncologist 2012;17:1120–1128.

• PubMed
BrownJCTroxelABSchmitzKH. Safety of weightlifting among women with or at risk for breast cancer-related lymphedema: musculoskeletal injuries and health care use in a weightlifting rehabilitation trial. Oncologist 2012;17:1120–1128. )| false
• Search Google Scholar
• Export Citation